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ABSTRACT 
Purpose: This is a head-to-head comparison between  Gallium-68 Prostate Specific 
Membrane Antigen (68Ga-PSMA-11) and 18F-Fluciclovine Positron Emission 
Tomography/Computed Tomography (PET/CT) in a series of 10 patients with prostate 
cancer (PCa) recurrence. Methods: 288 patients with PCa recurrence were enrolled in a 
prospective study of 68Ga-PSMA-11 PET/CT imaging for recurrent disease localization 
(NCT02940262). We retrospectively identified 10 patients who underwent clinical 
indicated 18F-Fluciclovine PET/CT prior enrollment. Results: The median time between 
both scans was 2.3 months (range 0.2-4.2). The median PSA value was 1.0 ng/ml (mean 
4.7 ng/ml; range 0.13-18.1) and 1.1 ng/ml (mean 6.2 ng/ml; range 0.24-31.3) at the time 
of 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT, respectively. 5/10 patients (50%) were 
negative on 18F-Fluciclovine PET/CT but showed positive results on 68Ga-PSMA-11 
PET/CT. 2/10 patients (20%) had both positive 18F-Fluciclovine and 68Ga-PSMA-11 
PET/CT but 68Ga-PSMA-11 PET/CT showed additional lymph nodes (LN) metastasis. 
3/10 patients (30%) had both negative 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT. 
Conclusion: This case series suggests improved detection rates of 68Ga-PSMA-11 when 
compared to 18F-Fluciclovine PET/CT in patients with recurrent PCa. Prospective trials 
designed to directly compare 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT should be 
initiated. 
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INTRODUCTION  
Localizing recurrent PCa with PET/CT imaging is clinically relevant as these patients can 
undergo salvage therapies with curative intent (1). Identifying recurrence site(s) with a 
high accuracy is important to select the best therapeutic approach. Several molecular 
imaging approaches have been proposed over the last decade. The best results for 
assessing patients with PCa recurrence were obtained with 18F-Fluciclovine and PSMA-
targeted PET radiotracers (2–5).  
18F-Fluciclovine or Axumin™ (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic 
acid) is a synthetic amino acid and likely a substrate of L amino acid (LAT1 in particular) 
and the alanine-serine-cysteine (ASC) transporters (specifically ASCT2) (6). The results 
obtained of the first prospective studies led to Food and Drug Administration (FDA) 
approval in 2016 and to the Center for Medicare and Medicaid Service (CMS) 
reimbursement in 2017 for patients with PCa recurrence (7). Thus it serves as a reference 
standard for evaluating other PET prostate cancer approaches.  
Prostate specific membrane antigen (PSMA) is a membrane bound metallo-
peptidase over expressed at high levels in 90-100% of PCa lesions (8). 68Ga-PSMA-11 is 
a highly specific urea-based inhibitor (Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)]) that 
internalizes upon ligand binding (8). 68Ga-PSMA-11 PET/CT demonstrates high efficacy 
in restaging PCa and is thus widely used in clinical trials and routine practice worldwide 
(2,4,9). These investigations reported also a favorable tumor to background ratio for 68Ga-
PSMA-11 to detect PCa lesion(s) and a high sensitivity for lesion detection even at low 
serum PSA values (PSA < 2ng/mL) (2).  
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To date there is only one single case report of a patient imaged with both 18F-
fluciclovine and 18F-radiolabeled PSMA-ligand (18F-DCFPyL) PET/CT (10) and no head-
to-head comparison between 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT has been 
published. Here we report the first case series of 10 patients with recurrent PCa who 
underwent both 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT. While we are aware that 
the present case series can at best provide the impetus for a large prospective trial we 
nevertheless felt that these observations are worthwhile reporting. 
 
MATERIALS AND METHODS 
Patient Population 
From October 2016 to November 2017, 288 patients with PCa recurrence were 
enrolled in a prospective study of 68Ga-PSMA-11 PET/CT imaging for recurrent disease 
localization (NCT02940262). The institutional review board approved this study (IRB#16-
001095) and all subjects signed a written informed consent. We retrospectively identified 
10 patients who underwent clinical indicated 18F-Fluciclovine PET/CT at other institutions 
within 4 months prior to 68Ga-PSMA-11 PET/CT. We obtained all DICOM files and clinical 
reports of 18F-Fluciclovine PET/CT scans to perform a head-to-head image analysis. 
Patient characteristics are listed in Table 1. Four patients had a history of primary surgery 
and salvage radiation therapy (SRT) (Patient #2, #4, #5, #10), two had primary surgery 
and adjuvant radiation therapy (Patient #6, #9), two had primary surgery only (Patient #7, 
#8) and two had undergone a primary combination therapy of external beam radiation, 
brachytherapy and androgen deprivation (Patients #1 and #3). All patients had prior 
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inconclusive or negative imaging tests within 3 months before the 18F-Fluciclovine 
PET/CT study: CT in 6/10 patients (Patients #1, #2, #3, #8, #9, #10), mpMRI (multi-
parametric magnetic resonance imaging) in 5/10 patients (Patients #2, #4, #5, #7, #8), 
18F-Fluoride PET/CT in 5/10 (Patients #1, #3, #5, #9, #10) and 11C-Choline PET/CT in 
2/10 patients (Patients #2, #6). 
PET/CT Imaging Acquisition 
68Ga-PSMA-11 PET/CT imaging was performed according to recent guidelines 
(11) with a 64-detector PET/CT device (Biograph True Point 64 or Biograph mCT; 
Siemens). 68Ga-PSMA-11 was used as the PSMA ligand (8). The median injected dose 
was 196 MBq (range 137-322 MBq). To reduce bladder activity patients received 20 mg 
of intravenous furosemide at the time of tracer injection. The median uptake period was 
62 min (range 53-68 min). A diagnostic CT scan (200-240 mAs, 120 kV) was performed 
after intravenous injection of contrast agent (if no contraindication) followed by the whole 
body PET image acquisition (2-4 min/bed position).  
18F-Fluciclovine PET/CT was performed at each site according to manufacturer 
dosing and administration guidelines (6). 18F-Fluciclovine was manufactured by 
automated radio synthesis (12). Patients were scanned after avoiding significant exercise 
for at least 24 h to minimize the muscular background, after fasting for at least 4 h to 
normalize amino acid levels and immediately after voiding. The median injected dose was 
371 MBq (range 337-396). The median uptake period was 4 min (range 2-15 min). A non-
diagnostic CT scan PET was performed for attenuation correction followed by PET image 
acquisition (5 min/bed position in the pelvis, 3 min/bed position in the remainder of the 
body).  
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PET/CT Imaging Analysis 
18F-Fluciclovine and 68Ga-PSMA-11 PET/CT images were co-registered and 
analyzed by an experienced nuclear medicine physician according to recent 
recommendations (6,11,13) using OsiriX: any focal uptake above surrounding 
background and not associated with physiological uptake or known pitfalls (14) was 
considered suspicious for malignancy. Based on TNM staging the following regions were 
systematically analyzed: prostate bed/ seminal vesicle remnants (T), pelvic LN (N) 
(internal Iliac, obturator, external Iliac, perirectal, pre-sacral, common Iliac), extra-pelvic 
LN (M1a) (retro-peritoneal, inguinal, chest, other), bone (M1b) and other visceral organs 
(M1c). 
 
RESULTS 
PET/CT results and detailed findings are listed in Tables 1 and 2. The median time 
between both scans was 2.6 months (range 0.2-4.2). The median PSA value was 1.0 
ng/ml (mean 4.7 ng/ml; range 0.13-18.1) and 1.1 ng/ml (mean 6.2 ng/ml; range 0.24-31.3) 
at the time of 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT, respectively. Recurrence sites 
were localized by 18F-Fluciclovine PET/CT in only 2/10 patients (20%) while 68Ga-PSMA-
11 PET/CT detected recurrence sites in 7/10 patients (70%). Five of 8 patients (63%) with 
negative 18F-Fluciclovine PET/CT studies had positive 68Ga-PSMA-11 PET/CT findings 
(Patients #1, #2, #5, #9, #10). One patient had positive findings for local recurrence on 
both scans but the 68Ga-PSMA-11 PET/CT study revealed additional extra-pelvic LN 
involvement (Patient #3). One patient had positive findings for single external iliac LN 
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recurrence on both scans but the 68Ga-PSMA-11 PET/CT study revealed additional 
obturator LN involvement (Patient #7). Three patients had concordantly negative scans 
(Patient #4, #6, #8). No difference was observed between our 18F-Fluciclovine PET/CT 
analysis and the original 18F-Fluciclovine PET/CT clinical reports. 
Specifically, the 5 patients with negative 18F-Fluciclovine but positive 68Ga-PSMA-
11 PET/CT study had the following findings. Patient #1 had multiple PSMA-positive 
lesions involving a small right external iliac LN (5 mm, SUVmax 7.7), multiple small 
retroperitoneal LN (4 to 5 mm, SUVmax 17), a right hilar LN (SUVmax 4) and a focal T8 
vertebrae bone lesion (Fig. 1). He then received androgen deprivation therapy (ADT). In 
patient #2 intense PSMA-11 uptake in a solitary osteoblastic T11 lesion (SUVmax 6) and 
faint PSMA-11 uptake in multiple bilateral common iliac and presacral LN (6 to 8 mm, 
SUVmax 2.0), as well as multiple bilateral lung nodules (6-10 mm, SUVmax 2.6) were 
evident (Fig. 2). He received proton therapy focused on T11 metastasis and refused any 
systemic treatment. In patient #5, four small perirectal LN showed mild PSMA-11 uptake 
(3 to 4 mm, SUVmax 2.9) (Fig. 3). His referring physician opted for active surveillance. In 
Patient #8 intense PSMA-11 uptake in multiple left pelvic LN (4 to 8 mm, SUVmax 12.6), 
retroperitoneal LN (4 to 6 mm, SUVmax 10.3) and supra-diaphragmatic LN (4 to 8 mm, 
SUVmax 16.1) were seen (Fig. 4). The patient received ADT. Finally, Patient #10 had a 
single tiny right upper common iliac LN with intense PSMA-11 uptake (3 mm, SUVmax 
5.3) (Supplemental Fig. 1). He received focused ablative RT and ADT initiation was put 
on hold. 
The two patients with a positive 18F-Fluciclovine PET/CT study had the following 
findings. Patient #3 had a small Fluciclovine-positive local recurrence (SUVmax 3.5) 
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whereas 68Ga-PSMA-11 PET/CT showed a much larger local recurrence with intense 
uptake (SUVmax 8.9). Moreover, 68Ga-PSMA-11 PET/CT demonstrated additional 
abnormal retroperitoneal LNs (8 to 10 mm, SUVmax 4.7) (Fig. 5; Supplemental Fig. 2). 
The patient received ADT. Patient #7 had a Fluciclovine-positive right external iliac LN 
recurrence (7 mm, SUVmax 4.9). 68Ga-PSMA-11 uptake was much more intense 
(SUVmax 8.9). In addition, 68Ga-PSMA-11 PET/CT demonstrated an additional abnormal 
tiny right obturator LN (4 mm, SUVmax 3.0) (Supplemental Fig. 3). The patient underwent 
unilateral right pelvic LN dissection. Three out of eight resected LN were positive for 
metastatic adenocarcinoma. 
Patients #4, #6 and #8 had concordantly negative 68Ga-PSMA-11 PET/CT and 18F-
Fluciclovine PET/CT. Patient #4 and #6 were monitored for PSA changes whereas 
Patient #8 underwent SRT to both prostate bed and pelvic LN.  
 
DISCUSSION  
We are aware that the results obtained in this current small case series do not 
indicate superiority of 68Ga-PSMA-11 over 18F-Fluciclovine PET/CT imaging. However, 
findings of the two tests were so strikingly different that we felt a brief report would be 
prudent. This also seemed justified, as no direct comparisons between these two tests 
have been published. 
While 7/10 studies (70%) were positive with 68Ga-PSMA-11, 8/10 18F-Fluciclovine 
scans were negative (80%), and disease extent was underestimated in both patients with 
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a positive 18F-Fluciclovine studies. Surprisingly, four 18F-Fluciclovine PET/CT scans were 
negative despite fairly extensive disease on 68Ga-PSMA-11 PET/CT scans.  
While extensive evidence has been established to support the use of 68Ga-PSMA-
11 PET/CT imaging even in patients with PCa biochemical recurrence at very low serum 
PSA levels (2,9) much less is known about the 18F-Fluciclovine performance.  
The main study which led the FDA approval for 18F-Fluciclovine was a 
retrospective analysis of 596 patients (3). The detection rate in the whole population 
(mean PSA 5.43 ng/mL) was 67.7% and it was 41.4% in the lowest quartile of serum PSA 
levels (< 0.79 ng/ml). Several studies reported a better diagnostic performance for 68Ga-
PSMA-11 PET/CT (9). The high accuracy in the detection of PCa metastases at very low 
serum PSA levels and the high sensitivity for detecting small lesions were considered the 
strength of PSMA based imaging (2,4,9).  
The high false negative rate of 18F-Fluciclovine scans in the current patients with 
relatively high serum PSA levels is concerning. Bone marrow and mostly muscle 
background activity (Fig. 5A) may have interfered with detection of extra-prostatic lesions.  
There is of course a significant selection bias in the current case series. Patients 
likely had negative 18F-Fluciclovine PET/CT studies and were therefore referred for 68Ga-
PSMA-11 PET/CT. Moreover, the median time interval between both scans was 2.6 
months which likely favored lesion detection with 68Ga-PSMA-11 PET/CT. But the median 
PSA levels increase between the two scans was only 0.1 ng/ml (range 0.03-13.2).  
Another important limitation is that histological confirmation of PSMA-positive 
lesions was available in only one patient (Patient#7) who underwent surgery. This is 
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because histological verification of lesions in patients with PCa recurrence is not routinely 
done. PSMA-positive lesions were not biopsied. Two patients received focal ablative 
radiation therapy after the scans (Patients #2, #10) whereas the others had non-focal 
treatment (ADT or SRT to both prostate bed and pelvic LN) or active surveillance. 
Therefore we cannot exclude that these PSMA-positive lesions were in fact false positive. 
CONCLUSION 
This case series suggests improved detection rates of 68Ga-PSMA-11 when 
compared to 18F-Fluciclovine PET/CT in patients with recurrent PCa. While far from 
definitive evidence for superiority, the observation strongly supports the initiation of 
prospective trials to directly compare the performance of 68Ga-PSMA-11 and 18F-
Fluciclovine PET/CT.  
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TABLES AND TABLES LEGENDS 
Table 1: Patients characteristics and PET/CT scans results 
PSA levels is ng/ml. 
Abbreviations: XRT: External Beam Radiation therapy, Brachy. : Brachytherapy, ADT: Androgen Deprivation therapy, RP: radical 
prostatectomy, SRT: Salvage radiation Therapy, mpMRI: multiparametric magnetic resonance imaging, Choline: 11C-Choline PET/CT, 
Na-F: 18F-Fluoride PET/CT; Met.: metastasis. 
 
Patient 
Number 
# 
Age Initial PSA 
Gleason 
Score pTNM Primary therapy 
Date of 
primary 
therapy 
Salvage 
Therapy 
Date of 
salvage 
therapy 
Prior Imaging within 
past 3 months 18F-Fluciclovine 68Ga-PSMA-11 
Management 
strategy  
After 68Ga-PSMA-11 
#1 65 7.8 4+3=7 cT2c XRT + Brachy. + ADT 2014     CT + Na-F 0 N1 M1aM1b ADT 
#2 76 7.17 4+3=7 pT3b N0 Mx RP 2009 SRT + ADT 2012 CT + mpMRI + Choline  0 N1 M1bM1c Proton therapy on bone met. 
#3 63 20.6 4+4=8 NA XRT + Brachy. + ADT 2015     CT+ Na-F  T+  T+ M1a ADT 
#4 72 NA 3+4=7 pT2c N0 Mx RP 2002 SRT + ADT 2016 mpMRI 0 0 Active surveillance 
#5 78 5.1 4+5=9 pT2b RP 2009 SRT 2012 mpMRI+ Na-F 0 N1 Active surveillance 
#6 67 4.5 4+5=9 pT3b, N0 RP + Adj. XRT + ADT 2015     Choline 0 0 Active surveillance 
#7 72 NA 4+3=7 pT3b RP 2017   mpMRI N1 N1 LN dissection 
#8 71 7.9 3+4=7 pT2c N0 Mx RP 2014   CT + mpMRI 0 0 SRT 
#9 74 5 NA NA RP + Adj. XRT 2008 ADT 2013-2017 CT+ Na-F 0 N1 M1a ADT 
#10 70 6 5+4=9 pT2 N0 Mx RP 2011 SRT 2015 CT+ Na-F 0 N1 
Ablative RT on 
single LN met. 
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Table 2 : PET/CT detailed finding.  
Abbreviations: LN: Lymph Node; Met: metastasis. 
Patient 
Number 
# 
PET/CT Probe Date PET/CT 
PSA at 
PET/CT 
ng/ml 
Positive 
Scan T 
Prostate fossa 
(T) Analysis  
Detailed findings 
SUV
max N 
Pelvic Lymph Nodes (N) 
Analysis 
Detailed findings 
SUV
max M 
Extra-Pelvic (M)  
Analysis 
Detailed findings 
SUV
max 
#1 18F-Fluciclovine 4/12/2017 10.6 0 0   0   0   
 68Ga-PSMA-11 5/19/2017 10.9 1 0   1 1 External iliac LN (5 mm) 7.7 1 
3 Retroperitoneal LN (4-5 mm) 
1 Thoracic LN 
1 Bone Met (T8) 
17.1 
4.4 
5.1 
#2 18F-Fluciclovine 3/16/2017 12.27 0 0   0   0   
 68Ga-PSMA-11 6/7/2017 12.66 1 0   1 Multiple common iliac  and presacral LN (6-8 mm) 2 1 
Multiple Lung nodules (6-10 mm) 
1 Bone Met (T11) 
2.6 
6 
#3 18F-Fluciclovine 3/15/2017 18.10 1 1 Faint localized uptake in left lobe 3.5 0   0   
 68Ga-PSMA-11 7/10/2017 31.30 1 1 Intense Diffuse Bilateral uptake 8.9 0   1 
Multiple retroperitoneal LN  
(8-10mm) 4.7 
#4 18F-Fluciclovine 5/25/2017 1.50 0 0   0   0   
 68Ga-PSMA-11 7/24/2017 1.60 0 0   0   0   
#5 18F-Fluciclovine 3/23/2017 0.22 0 0   0   0   
 68Ga-PSMA-11 7/31/2017 0.30 1 0   1 4 perirectal LNs  (3-4 mm) 2.9 0   
#6 18F-Fluciclovine 5/9/2017 0.13 0 0   0   0   
 68Ga-PSMA-11 9/15/2017 0.24 0 0   0   0   
#7 18F-Fluciclovine 10/5/2017 0.50 1 0   1 1 External iliac LN (7 mm) 4.9 0   
 68Ga-PSMA-11 10/11/2017 0.65 1 0   1 1 External iliac LN (7mm) 1 Obturator LN (4 mm) 
14.1 
3.0 0   
#8 18F-Fluciclovine 9/19/2017 0.30 0 0   0   0   
 68Ga-PSMA-11 10/25/2017 0.33 0 0   0   0   
#9 18F-Fluciclovine 8/8/2017 3.04 0 0   0   0   
 68Ga-PSMA-11 10/26/2017 3.90 1 0   1 Multiple common and external iliac LN (4-8 mm) 12.6 1 
Multiple retroperitoneal LN (4-6mm) 
Multiple thoracic LN (4-8mm) 
10.3 
16.1 
#10 18F-Fluciclovine 10/11/2017 0.20 0 0   0   0   
 68Ga-PSMA-11 11/13/2017 0.30 1 0   1 1 common iliac LN (3 mm) 5.3 0   
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FIGURES LEGENDS 
Figure 1:  
 
Patient #1 had a negative 18F-Fluciclovine PET/CT (bottom row) while he had a positive PSMA-11 
PET/CT (top row). Yellow arrows show intense PSMA-11 uptake in a focal T8 vertebrae bone lesion, 
right external iliac LN (5 mm), and tiny retroperitoneal LN (4 to 5 mm). There was no 18F-Fluciclovine 
uptake in the corresponding structures on the 18F-Fluciclovine PET/CT. The white arrow indicates 
urinary excretion of PSMA-11 in a ureteral dilation.  
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Figure 2:  
 
Patient #2 had a negative 18F-Fluciclovine PET/CT (bottom row) and a positive 68Ga-PSMA-11 
PET/CT (top row). Yellow arrows show PSMA-11 uptake in a T11 vertebrae bone lesion, lung 
micronodules, presacral LN and common iliac LN. There was no 18F-Fluciclovine uptake in the 
corresponding structures on the 18F-Fluciclovine PET/CT.  
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Figure 3: 
 
Patient #5 had a negative 18F-Fluciclovine PET/CT (bottom row) and a positive 68Ga-PSMA-11 PET/CT 
(top row). Yellow arrows show PSMA-11 uptake in tiny peri-rectal LN (3 to 4 mm). The corresponding 
LN showed no 18F-Fluciclovine uptake.  
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Figure 4: 
 
Patient #8. Maximum Intensity Projections (MIP) of 18F-Fluciclovine PET (A, left panel) and 68Ga-PSMA-
11 PET (B, right panel). The yellow arrows (B) indicate intense PSMA-11 uptake in multiple pelvic LN, 
abdominal LN, thoracic LN and supra-clavicular LN. The corresponding LN showed no 18F-Fluciclovine 
uptake (A).  
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Figure 5: 
 
Patient #3. Maximum Intensity Projections (MIP) of 18F-Fluciclovine PET (A, left panel) and 68Ga-PSMA-
11 PET (B, right panel). The blue arrow (A) indicates a faint and limited uptake of 18F-Fluciclovine in 
the left prostate gland. The yellow arrows (B) indicate diffuse and intense 68Ga-PSMA-11 uptake in the 
prostate gland and in extra-pelvic LN. 
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SUPPLEMENTAL FIGURES LEGENDS  
Supplemental Figure 1:  
 
Patient #10. Patient #10 had a negative 18F-Fluciclovine PET/CT scan a positive 68Ga-PSMA-11 
PET/CT. Yellow arrows show PSMA-11 uptake in a single tiny right upper common iliac LN (3 mm).  
A: Maximum Intensity Projections (MIP) of 68Ga-PSMA-11 PET; B: fused 68Ga-PSMA-11 PET/CT 
coronal view; C: CT coronal view; D: fused 68Ga-PSMA-11 PET/CT axial view; E: CT axial view.   
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Supplemental Figure 2:  
 
Patient #3 had a positive 18F-Fluciclovine PET/CT (bottom row) for a local recurrence only with a faint 
and limited uptake in the left prostate gland (E,F; blue arrows). The 68Ga-PSMA-11 PET/CT (top row) 
showed a diffuse and intense uptake in the whole prostate gland (A,B; yellow arrows) and PSMA-11 
uptake in multiple extra-pelvic LN (C,D, yellow arrows). The corresponding LN showed no 18F-
Fluciclovine uptake (G,H). 
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Supplemental Figure 3: 
 
Patient #7 had a positive 18F-Fluciclovine PET/CT (bottom row) for a right external iliac LN (C; blue 
arrows). The 68Ga-PSMA-11 PET/CT (top row) showed a much intense uptake in the corresponding 
LN (A; yellow arrow) and PSMA-11 uptake in a tiny 4 mm right obturator LN (B, yellow arrow). The 
corresponding LN showed no 18F-Fluciclovine uptake (D). 
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